Summit Therapeutics (SMMT) revenue breakdown
By product, Licensing agreements is the largest at 99% of fiscal 2019 revenue, growing 371% a year over 1 years.
By region, Latin America is the largest at 78% of fiscal 2019 revenue, growing 273% a year over 2 years.
Revenue by product
Fiscal years, as Summit Therapeutics reports them in its 10-K filings; fiscal 2019 total $57M.
| Products | 2018 | 2019 | Share |
|---|---|---|---|
| Licensing agreements | $12M | $57M | 99% |
| Research collaboration agreement | $310,000 | $327,000 | 1% |
Revenue by region
Fiscal years, as Summit Therapeutics reports them in its 10-K filings; fiscal 2019 total $743,000.
| Regions | 2018 | 2019 | 2019 | Share |
|---|---|---|---|---|
| Latin America | $42,000 | $662,000 | $583,000 | 78% |
| United States | $12M | $56M | $160,000 | 22% |
| Europe | — | $327,000 | — | — |
| Europe | $310,000 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SMMT.
Open SMMT in InvestinglyQuestions
Where does Summit Therapeutics make its money?
In fiscal 2019, by product: Licensing agreements $57M, Research collaboration agreement $327,000.
From Summit Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.